Panitumumab

WikiDoc Resources for Panitumumab
Articles
Most recent articles on Panitumumab Most cited articles on Panitumumab Review articles on Panitumumab Articles on Panitumumab in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Panitumumab Images of Panitumumab Photos of Panitumumab Podcasts & MP3s on Panitumumab Videos on Panitumumab
Evidence Based Medicine
Cochrane Collaboration on Panitumumab Bandolier on Panitumumab TRIP on Panitumumab
Clinical Trials
Ongoing Trials on Panitumumab at Clinical Trials.gov Trial results on Panitumumab Clinical Trials on Panitumumab at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Panitumumab NICE Guidance on Panitumumab NHS PRODIGY Guidance FDA on Panitumumab CDC on Panitumumab
Books
Books on Panitumumab
News
Panitumumab in the news Be alerted to news on Panitumumab News trends on Panitumumab
Commentary
Blogs on Panitumumab
Definitions
Definitions of Panitumumab
Patient Resources / Community
Patient resources on Panitumumab Discussion groups on Panitumumab Patient Handouts on Panitumumab Directions to Hospitals Treating Panitumumab Risk calculators and risk factors for Panitumumab
Healthcare Provider Resources
Symptoms of Panitumumab Causes & Risk Factors for Panitumumab Diagnostic studies for Panitumumab Treatment of Panitumumab
Continuing Medical Education (CME)
CME Programs on Panitumumab
International
Panitumumab en Espanol Panitumumab en Francais
Business
Panitumumab in the Marketplace Patents on Panitumumab
Experimental / Informatics
List of terms related to Panitumumab

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Panitumumab (ABX-EGF) is a fully human monoclonal antibody specific to the EGF receptor (see illustration)[3]. It was FDA approved for the first time in September 2006, for the "the treatment of EGFR-expressing metastatic colorectal cancer with disease progression" despite prior treatment . Panitumumab is manufactured by Amgen and marketed as Vectibix in the USA.

The compound works by binding to the extracellular domain of the EGFR (epidermal growth factor receptor) preventing its activation. This in turn, results in halting of the cascade of intracellular signals dependent on this receptor.

Panitumumab is produced by immunization of transgenic mice (xenomouse), that are able to produce human immunoglobulin light and heavy chains. After immunization of these animals a specific clone of B cells that produced an antibody against EGFR was selected and immortalized in Chinese hamster ovary (CHO) cells. These cells are then used for the full scale manufacture of the antibody.

Although they both target the EGFR, panitumumab (IgG2) and cetuximab (IgG1) differ in their isotype and they might differ in their mechanism of action. Monoclonal antibodies of the IgG1 isotype may activate the complement pathway and mediate ADCC (antibody-dependent cellular cytotoxicity) better than their IgG2 counterparts, hence although they have not been documented, differences in the responses in treatments with these two antibodies might be expected. [4]

Further readings

Philippe Rougier, Emmanuel Mitry, Sophie Dominguez. Les Cancers Digestifs ; Springer , September 1, 2006, page=291 ; language=French